Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-09-18 Share Issue/Capital Cha…
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("COMMUNIQUE DE PRESSE") dated September 18, 2024, announcing the launch of a capital increase ("augmentation de capital") with an initial amount of €10.3 M. It details the terms, including the subscription price (€1.60), the priority period for existing shareholders (September 18 to 26, 2024), and the structure involving an offer to the public and a global placement. This clearly falls under the category of financing activities and capital structure changes. Reviewing the definitions: - 10-K: No, this is not an annual report. - ER: No, this is not just an earnings release. - IR: No, this is not a comprehensive interim financial report. - CAP (Capital/Financing Update): This perfectly matches the content, which is an announcement of a capital increase to finance activities. - SHA (Share Issue/Capital Change): While related, CAP is more specific for fundraising announcements, whereas SHA often refers to the resulting change or a stock split. Given the focus on the fundraising mechanism and amount, CAP is the most appropriate primary classification. Therefore, the document is classified as a Capital/Financing Update (CAP).
2024-09-18 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the launch of a capital increase for an initial amount of €10.3 million, detailing the terms, subscription price, priority period, and the intended use of funds (financing activities until at least the end of 2024). This clearly falls under the category of financing activities and capital structure changes. The specific filing code matching this description is 'CAP' (Capital/Financing Update). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), as it is highly specific to a financing event.
2024-09-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a significant operational milestone (reaching half of the targeted patient recruitment for the EFICAS study) and future publication timelines. This format, which communicates key business updates and operational progress rather than comprehensive financial statements (like 10-K or IR) or formal voting results, strongly suggests an Earnings Release (ER) or a general announcement. Since it focuses on operational progress and future milestones rather than just summarizing quarterly financial figures, it fits best as a general announcement or press release detailing business progress. Given the options, 'ER' (Earnings Release) is often used for significant operational updates accompanying financial results, but since this is purely operational news about a clinical trial, and it is not a formal regulatory filing like a 10-K or a short notice about a report publication (RPA/RNS), it is best classified as a general announcement. However, in financial databases, press releases detailing operational progress are often grouped with Earnings Releases (ER) if they are timely, or sometimes fall under Regulatory Filings (RNS) if they are mandatory disclosures. Since it is a 'COMMUNIQUE DE PRESSE' detailing progress that impacts future earnings/market access, ER is a strong candidate, but RNS is the most appropriate fallback for non-standard, timely announcements. Given the context of a major clinical trial update, it is a significant corporate event announcement. If we strictly follow the definitions, it is not an ER (which is usually financial results highlights), nor an RPA (it's the news itself, not an announcement *of* a report). It is a significant corporate update. I will classify it as RNS (Regulatory Filings / General regulatory announcements) as it is a press release detailing material, non-financial operational progress, which often defaults to this category when specific operational codes are missing, or ER if we interpret 'key highlights' broadly. Given the content is about clinical trial progress and future publication dates, it is a material event disclosure. I will lean towards RNS as the most general fit for a press release not covered elsewhere, though ER is plausible if this was released alongside quarterly results. Since it is a standalone press release, RNS is safer.
2024-09-12 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a milestone update regarding the EFICAS study (half of enrolments reached) and anticipated publication dates for study results. This format, focusing on key operational and scientific updates rather than comprehensive financial statements (like 10-K or IR) or formal voting results, strongly suggests an Earnings Release (ER) or a general announcement. Since it is a press release detailing operational progress and future publication timelines, it fits best under the Earnings Release category, which often includes operational highlights alongside financial context (though financial context is minimal here, the structure is typical of an ER announcement). It is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. Given the context of a major operational update announced via press release, ER is the most appropriate fit among the provided options, although it could also be considered RNS if ER was too narrow. However, updates on study progress and publication timelines are standard components of ERs. H1 2024
2024-09-12 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and explicitly states it announces "résultats semestriels 2024" (2024 half-year results). It contains key financial highlights (revenue, net loss, cash burn) for the six months ended June 30, 2024, and includes a simplified income statement for the 6-month periods of 2024 and 2023. This structure—a press release summarizing period-specific financial performance for a period shorter than a year—is the definition of an Earnings Release (ER). Although it mentions the full 'rapport financier semestriel 2024 est publié ce jour' (the 2024 half-year financial report is published today), the document provided is the initial, high-level announcement, making ER the most appropriate classification over the comprehensive Interim Report (IR) or a Report Publication Announcement (RPA), given its content focus on results highlights and management commentary. It is not a 10-K (Annual Report), nor is it a generic RPA because it contains substantial financial data, not just a notice of publication. H1 2024
2024-09-06 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2024 INTERIM FINANCIAL REPORT' and covers the six-month period ended June 30, 2024. It contains comprehensive financial statements (Balance Sheet, Income Statement, Cash Flow Statement), notes to the financial statements, and a review of operations. It is not a short announcement or a certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-09-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.